Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.87 |
| ▸ | CA1 | P00915 | 5/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28156543 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL5090059 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL1665997 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL10706703 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL1668977 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL8533142 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL3628614 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL3859929 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL6119566 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL27624866 | 0.98 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | claimed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | claimed |
| CN-116648451-A | Antagonist compounds | 阿道尔克斯治疗有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116438166-A | N-substituted 4- (1, 3-aryloxazol-2-yl) phenyl compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | claimed |
| CN-115279747-A | Novel fYN and VEGFR2 kinase inhibitors | 罗达制药生物技术有限责任公司 | 2022-11-01 | — | — | CN | claimed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | claimed |
| CN-113613722-A | Novel imidazole-pyrazole derivatives | 豪夫迈·罗氏有限公司 | 2021-11-05 | — | — | CN | claimed |
| WO-2021060453-A1 | CROSSLINKED OPTICALLY ACTIVE SECONDARY AMINE DERIVATIVE | 大日本住友製薬株式会社 | 2021-04-01 | — | — | WO | claimed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
| WO-1999007413-A1 | SUBSTANCE P INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1999-02-18 | — | — | WO | claimed |
| US-5869499-A | Benzyloxyquinuclidines as substance P antagonists | PFIZER INC (US) | 1999-02-09 | — | — | US | claimed |
| US-5837711-A | Substituted quinuclidines as substance P antagonists | PFIZER INC. (US) | 1998-11-17 | — | — | US | claimed |
| WO-1998027815-A1 | SUBSTITUTED AMINOQUINOLINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-07-02 | — | — | WO | claimed |
| US-5750535-A | Pharmaceutical agents for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1998-05-12 | — | — | US | claimed |
| CN-1154240-A | NK-1 receptor antagonists for treatment of cancer | PFIZER (US) | 1997-07-16 | — | — | CN | claimed |
| CN-1132072-A | NK-1 receptor antagonists for the treatment of nerve injury and stroke | PFIZER (US) | 1996-10-02 | — | — | CN | claimed |
| EP-0665843-A1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-08-09 | — | — | EP | claimed |
| WO-1994010170-A1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-05-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | CA2 3949/4885CA1 4855/4885MAPK1 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.